Explore the Agenda
8:10 am Registration & Light Refreshments
9:00 am Chair’s Opening Remarks
Preclinical Framework for Radiopharmaceuticals: Integrating Radiobiology, Preclinical Dosimetry, & Pharmacokinetics to Optimize Early-Stage Therapeutic Efficacy and Safety
9:15 am Translating PK & Dosimetry for Faster, Safer Phase 0/FIH Progression
- Defining ABD147 PK and tumor uptake in murine DLL3 models
- Translating preclinical dosimetry to human PBPK projections
- Informing FIH dosing through interspecies PK/dosimetry scaling
New Company for 2026
9:45 am Session Details to be Confirmed
10:15 am Morning Networking Break
Scrutinizing Novel Targets Including Trop-2, DLL3 & CEACAM5 as Potential New Targets with Optimal Expression to Enhance Target Validation & Translational Relevance & Move Beyond “Me-Too” Drugs
11:00 am Exploring Case Studies & Supporting Preclinical Data Behind Targeting PD-L1, KLK3 & B7-H3 With Radiopharmaceuticals
- Demonstrating strong tumor uptake and imaging performance in Trop-2–positive cancers
- Highlighting opportunities to use Trop-2 expression for patient selection and treatment planning
- Establishing Trop-2 as a promising candidate for integrated diagnostic and therapeutic strategies
11:30 am Translating Immuno-Oncology Targets into Radioligand Precision Platforms
- Exploring how integrating antibody engineering with radioligand design enables precise delivery of therapeutic isotopes to immune-relevant tumor environments
- Showcasing how emerging immune-regulatory targets beyond PD-(L)1 offer novel pathways for targeted radioligand modulation
- Analyzing tumor-restricted glycoproteins as highly specific anchors for next-generation theranostic development
New Company for 2026
12:00 pm Lunch Break & Networking
Scrutinizing Novel Targets Including Trop-2, DLL3 & CEACAM5 as Potential New Targets with Optimal Expression to Enhance Target Validation & Translational Relevance & Move Beyond “Me-Too” Drugs
1:00 pm Targeting the Extracellular Matrix: Overcoming Biological Barriers to Unlock Novel Therapeutic Opportunities
- Analyzing why components of the extracellular matrix (ECM) could be ideal targets for radioligand therapy
- Exploring challenges associated with delivering therapeutic doses when targeting components of the ECM
- Reviewing early development strategy for a novel fibrin targeted radioligand therapy
New Company for 2026
1:30 pm Roundtable Discussion: Defining the Next Generation of Radiopharmaceutical Targets
- Prioritizing target attributes beyond receptor density and expression to expand therapeutic reach
- Aligning target biology with alpha vs. beta emitter properties for more effective strategies
- Exploring novel opportunities in stromal markers like FAP and internalizing targets for durable responses
New Company for 2026
2:30 pm Afternoon Networking Break
Building Smarter Radiopharmaceuticals with Maximized Stability: Chelator & Linker Selection for Optimal Biodistribution & Half-Life
3:00 pm Linker Design Trends & Implications for Enhanced Radiopharmaceutical Agents’ PD/PK
- Covering the latest trends and innovations in linker design
- Appreciating implications for radiopharmaceutical properties
- Exploring strategies including plasma protein binding, covalent binding, charge and hydrophobicity, and enzymatic cleavage
3:30 pm Advancing Chelator Technologies for Enhanced Radiopharmaceutical Development
- Enhancing therapeutic performance by modifying drug properties for improved efficacy and safety
- Selecting optimal chelators to maximize stability and target delivery
- Optimizing pharmacokinetics and biodistribution to improve drug distribution and clearance for better clinical outcomes
New Company for 2026